Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESTRO 2021 | Quality assessment of breast cancer radiotherapy in SENOMAC

Sara Alkner, MD, Lund University, Lund, Sweden, discusses quality assurance in the SENOMAC trial (NCT02240472), which compared axillary lymph node dissection (ALND) and surveillance (sentinel lymph node biopsy only) in patients with clinically node-negative breast cancer. Treatment plans of patients in Sweden or Denmark differed in inclusion of axillary level I nodes in the clinical target volume (CTV). Level I nodes were included in patients who did not receive ALND in Denmark, whereas inclusion was site-dependent in Swedish patients. Analysis of CTV revealed inclusion of axillary level I nodes made no significant difference in the interpretation of data. This interview took place at the European Society for Radiotherapy and Oncology (ESTRO) 2021.